Antimyoclonic Effect of MK-801
- 1 August 1990
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 13 (4) , 329-338
- https://doi.org/10.1097/00002826-199008000-00008
Abstract
Summary Rat pups exhibit transient “developmental dyskinesias,” such as tremor and myoclonus, that are analogous to motor immaturities of the human neonate. Myoclonic jerks in the neonatal rat may reflect a developmental imbalance of excitatory and inhibitory neurotransmission. To test this hypothesis, spontaneous myoclonic jerks of naive rat pups (n = 200) were characterized behaviorally and pharmacologically. The frequency of myoclonus was high (154 ± 14 jerks/30 min) in the first week. The distribution of jerks included limbs (47%) (27% in forelimbs and 20% in hindlimbs), tail (30%), trunk (12%), and head (11%). Myoclonus constituted the predominant neonatal adventitious movement (81%). Myoclonic jerks were variable in intensity, focal and multifocal more often than generalized, and occurred when nonrespiratory movements were infrequent or absent, suggesting sleep. Myoclonic frequency significantly diminished after the second week; therefore, drug effects were studied in the first 7 days. Systemic injection of the novel noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 blocked neonatal myoclonus in a dose-dependent manner (ID50 = 0.67 mg/kg; r = 0.93). The nonselective excitatory amino acid (EAA) receptor antagonist kynurenic acid was ineffective. The EAA antagonist AP4 (1 and 10 mg/kg) also reduced myoclonic jerks, but other drugs, such as the selective glycine antagonist Iso-THAO (1 and 10 mg/kg), strychnine (0.5 mg/kg), clonazepam, and diazepam (1 mg/kg), were ineffective blockers. The putative agonists quisqualic acid (1–50 mg/kg) and NMDA (1–10 mg/kg) altered myoclonus only at behaviorally toxic doses. These data suggest that EAA receptors participate in developmental myoclonus of the neonatal rat and that developmental myoclonus may be a useful quantitative model of functional maturity of excitatory/inhibitory synapses. The efficacy of MK-801 also should be evaluated in drug- and lesion-induced myoclonus. Recognition of the high frequency and state dependence of spontaneous myoclonic jerks in neonatal rats may be important to neonatal antiepileptic drug studies.Keywords
This publication has 13 references indexed in Scilit:
- The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.Proceedings of the National Academy of Sciences, 1986
- Benign Neonatal Sleep MyoclonusArchives of Neurology, 1986
- Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterionsJournal of Medicinal Chemistry, 1986
- Benign Myoclonus of Early Infancy or Benign Non-Epileptic Infantile SpasmsNeuropediatrics, 1986
- Is there a “serotonergic syndrome” in neonatal rat pups?Pharmacology Biochemistry and Behavior, 1985
- Behavioral comparison of pentylenetetrazol, clonidine, chlordiazepoxide and diazepam in infant ratsPharmacology Biochemistry and Behavior, 1983
- Antiepileptic action of excitatory amino acid antagonists in the photosensitive baboon, papio papioNeuroscience Letters, 1983
- Restoration of shock‐suppressed behavior by treatment with (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo[a, d]cyclohepten‐5, 10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic propertiesDrug Development Research, 1982
- Postures, Motility and Respiration of Low‐risk Pre‐term InfantsDevelopmental Medicine and Child Neurology, 1979
- Ontogenetic Development of the Human Sleep-Dream CycleScience, 1966